Sanofi’s Easier to Use Hemophilia Drug Approved by US FDA
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, paving the way for a new type of ...
Pharmaceutical Technology on MSN1d
Soleno wins FDA approval for Prader-Willi hyperphagia treatment
Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...
BioWorld1d
First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars
Becoming the first treatment for rare genetic disorder Prader-Willi syndrome (PWS), breakthrough therapy drug DCCR (diazoxide choline) gained U.S FDA approval as Vykat XR the evening before March 27, ...
Pharmaceutical Technology1d
How bioconjugation is unlocking the next generation of drug development
Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...
Endovascular Today1d
Vasorum’s Celt ACD Plus Vascular Closure Device Approved by FDA
Vasorum USA, Inc. announced FDA approval of the Celt ACD Plus system, which is designed for rapid arterial puncture closure ...
Zacks Investment Research on MSN2d
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...
EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 ...
TMCnet3d
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile VANCOUVER, British Columbia, March 25, 2025 (GLOBE ...